Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives

Johannes Sievers, Rabea Voget, Feiteng Lu, Kathleen M. Garchitorena, Yuen Lam Dora Ng, Cindy H. Chau, Christian Steinebach, William D. Figg, Jan Krönke, Michael Gütschow*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction of fluorine into bioactive molecules has attracted much attention in drug development. For example, tetrafluorination of the phthalimide moiety of immunomodulatory drugs (IMiDs) has a strong beneficial effect on the ability to inhibit angiogenesis. The neomorphic activity of E3 ligase complexes is induced by the binding of IMiDs to cereblon. We investigated that a set of eight thalidomide analogs, comprising non- and tetrafluorinated counterparts, did not induce the degradation of neomorphic substrates (IKZF3, GSPT1, CK1α, SALL4). Hence, the antiangiogenic activity of fluorinated IMiDs was not triggered by neosubstrate degradation features. A fluorine scanning of non-traditional IMiDs of the benzamido glutarimide chemotype was performed. By measuring the endothelial cell tube formation, no angiogenesis inhibitors were identified, confirming the narrow structure–activity window of IMiD-induced antiangiogenesis.

Original languageEnglish
Article number129858
JournalBioorganic and Medicinal Chemistry Letters
Volume110
DOIs
StatePublished - 15 Sep 2024
Externally publishedYes

Keywords

  • Angiogenesis
  • Cancer therapy
  • Cereblon
  • Immunomodulatory drugs
  • Neosubstrates

Fingerprint

Dive into the research topics of 'Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives'. Together they form a unique fingerprint.

Cite this